Molecular Health and Axxam Partner to Advance Drug Discovery Target Identification

Combining clinical-molecular data insights with biological validation to pinpoint drug targets and validate leads for biopharmaceutical companies

MILAN, Italy and HEIDELBERG, Germany, June 04, 2025 — Axxam S.p.A., a leading provider of comprehensive early discovery services, and Molecular Health GmbH, a frontrunner in AI-driven development solutions, have announced a strategic partnership aimed at accelerating the discovery and validation of new therapeutic targets across various therapeutic areas.

The collaboration will leverage synergies to provide precise, clinically-driven solutions for identifying disease-to-target and target-to-lead candidates for the pharmaceutical and biotech sectors. This will be achieved by integrating Molecular Health’s Dataome platform into Axxam’s Discovery^MAXX, an integrated early drug discovery process that combines computational clinical-molecular insights with biological validation.

Dataome consolidates, integrates, and structures molecular, phenotypic, and clinical data from public, private, and proprietary sources. Its causal insights assist pharmaceutical companies in enhancing drug development, predicting drug safety, optimizing clinical trials, and making data-informed investment decisions.

Molecular Health utilizes advanced AI within Dataome to analyze comprehensive datasets, assisting clients in identifying novel drug targets with high potential. These computationally derived predictions will be integrated into Axxam’s discovery platform, which encompasses extensive expertise in biology, assay development, phenotypic and target-based screening, and compound profiling. This partnership will ensure that AI-derived targets undergo thorough experimental validation using advanced in-vitro technologies, including induced pluripotent stem cell (iPSC)-based models, to confirm biological and disease relevance and translational value.

“Identifying the correct target is a critical and challenging step in drug discovery. At Axxam, we firmly believe that biology-driven validation is essential for translating digital assessments and predictions into effective therapies,” stated Ciriaco Maraschiello, CEO of Axxam. “This strategic partnership between Axxam, a biology expert, and Molecular Health, an AI company focused on precision medicine, enables a new level of accuracy and efficiency in early drug discovery. This allows our clients to make quicker, more informed decisions in preclinical and clinical development.”

“Understanding molecular causalities and variants in phenotypes, diseases, and endotypes is crucial for pharma and biotech companies to improve efficiency and success rates in drug development,” said Friedrich von Bohlen, CEO of Molecular Health. “The integration of our data/AI-based knowledge, simulations, and predictions with Axxam’s preclinical biology and chemistry assays and expertise will lead to improved and accelerated outcomes in early drug discovery. Our joint clients will benefit from deeper insights, enhanced decision-making, and expanded options for drug discovery and clinical development programs.”

By connecting AI-powered clinical-molecular predictions with biological insight, Axxam and Molecular Health aim to provide next-generation discovery programs to pharmaceutical innovators globally.

About Axxam S.p.A.

Axxam S.p.A. is a leading provider of integrated discovery services in the life sciences industry. Within drug discovery, we support pharma, biotech companies, start-ups, patient foundations, and academic groups from hit identification to lead generation, across all therapeutic areas and target classes. Our services include assay development, high-throughput screening using Axxam’s compound collections (synthetic and natural) or client-provided collections, hit validation, hit-to-lead, and compound management. This science-driven approach is also used to identify bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic, and perfume industries. For more information, visit .

About Molecular Health GmbH

Molecular Health is a leader in data-driven software technologies for the pharmaceutical and biotechnology industries. For over a decade, the company has combined human expertise, data curation, and advanced analytics, including artificial intelligence, to transform biomedical knowledge into actionable insight.

The company’s Pharma AI solutions support indication and biomarker discovery, target identification and validation, clinical-trial design and simulation, endpoint optimization, and safety prediction. At the core of these capabilities is Dataome, Molecular Health’s technology that integrates and contextualizes biomedical, molecular, phenotypic, and drug data to reveal the etiology of health and disease.
For more information, visit .